Search Within

Mark Kris

Formats
  1. Journal Article (478)
  2. Meeting Abstract (355)
  3. Conference Paper (16)
  4. Book Section (9)
  5. Review (6)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (869)
  2. Solid Tumor Oncology Division (869)
  3. Thoracic Oncology (869)
  4. Department of Pathology and Laboratory Medicine (317)
  5. GSK Faculty (290)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Gregory Riely (220)
  2. Marc Ladanyi (189)
  3. Vincent Miller (172)
  4. Valerie Rusch (130)
  5. Maria Arcila (123)
  6. Jamie Chaft (107)

More People

Years
  1. 2025 (4)
  2. 2024 (18)
  3. 2023 (27)
  4. 2022 (21)
  5. 2021 (21)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (234)
  2. Journal of Thoracic Oncology (131)
  3. Clinical Cancer Research (65)
  4. Cancer (33)
  5. Lung Cancer (31)
  6. Annals of Oncology (24)

More Publications

Publishers
  1. American Society of Clinical Oncology (252)
  2. Elsevier Inc. (179)
  3. American Association for Cancer Research (105)
  4. Oxford University Press (47)
  5. Wiley Blackwell (36)
  6. Elsevier Ireland Ltd. (30)

More Publishers

Results (869)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of cabozantinib in ROS1-rearranged lung adenocarcinoma
    Meeting Abstract

    Guo, R.; Preeshagul, I.; Schoenfeld, A.; McCarthy, C.; Makhnin, A.; Plodkowski, A.; Ginsberg, M.; Davare, M.; Delasos, L.; Somwar, R.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histologic landscape of acquired resistance to osimertinib in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A.; Chan, J.; Rizvi, H.; Somwar, R.; Kubota, D.; Daneshbod, Y.; Chang, J.; Offin, M.; Arcila, M.; Pe'Er, D.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Novel germline mutations in DNA-damage repair and DNA replication identified in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Guo, R.; Duboff, M.; Kris, M.; Ladanyi, M.; Mandelker, D.; Zauderer, M.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab in resectable NSCLC patients: Immunophenotyping results from the interim analysis of the multicenter trial LCMC3
    Meeting Abstract

    Oezkan, F.; He, K.; Owen, D.; Pietrzak, M.; Cho, J. H.; Kitzler, R.; Pearson, R.; Rusch, V.; Chaft, J.; Suh, R.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers
    Meeting Abstract

    Offin, M.; Xu, C.; Jain, H.; Makhnin, A.; Hayes, S. A.; Plodkowski, A. J.; Halpenny, D.; Rudin, C. M.; Kris, M. G.; Drilon, A. E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial
    Meeting Abstract

    Li, B. T.; Shen, R.; Offin, M.; Buonocore, D. J.; Myers, M. L.; Venkatesh, A.; Razavi, P.; Ginsberg, M. S.; Ulaner, G. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer
    Meeting Abstract

    Lai, W. C. V.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Ginsberg, M. S.; Kris, M. G.; Beras, A.; Rekhtman, N.; Poirier, J. T.; Hellmann, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save